NEW YORK (GenomeWeb) — University of Pennsylvania spinout Liquid Biotech announced today that it has raised $2 million in seed financing from Japan's Oncolys Biopharma, which it said would be used to further develop and refine its proprietary circulating tumor cell (CTC) identification and isolation technology.

"The funding we have obtained gives us a good runway to develop proof-of-concept that our diagnostic test has the sensitivity to detect cancer in a clinical setting," Liquid Biotech COO Jeffrey Janco said in a statement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.